Advertisement

Topics

Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program

2018-10-30 14:05:14 | BioPortfolio

Published on BioPortfolio: 2018-10-30T14:05:14-0400

Clinical Trials [1350 Associated Clinical Trials listed on BioPortfolio]

Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice

The primary purpose of the study is to determine the effect of esomeprazole compared to placebo in patients from general practice who have previously been treated with proton-pump-inhibito...

Proton Pump Inhibitors Use in Patients With Psoriasis

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action wit...

The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.

Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.

Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine

There is substantial, continuing, and unexplained rise in prescribing of proton pump inhibitors. It is unknown whether their use in practice has corresponded to their licensed indications....

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

This is a research study that will investigate the effects of proton pump inhibitors (often used to treat stomach upset) on Gleevec® (a drug that is FDA-approved to treat some types of ca...

PubMed Articles [7495 Associated PubMed Articles listed on BioPortfolio]

Proton Pump Inhibitors and the Risk of Dementia: is There a Link?

Dementia is one of the most common neurodegenerative disorder among older populations around the world, and the incidence is increasing. Many epidemiologic studies have considered the association betw...

Adverse effects of proton pump inhibitors: fact or fake news?

The present review summarizes the past year's literature, both clinical and basic science, regarding potential adverse effects of proton pump inhibitors.

Proton pump inhibitors use and risk of hepatocellular carcinoma.

One cohort study using the Taiwan's database conducted by Kao et al published in Hepatology reported that proton pump inhibitors use was not associated with the risk of developing hepatocellular carc...

Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.

Children with obesity are more likely to suffer gastroesophageal reflux disease, requiring acid-suppression therapy with proton pump inhibitors (PPIs) and no guidelines regarding dosing.

Use of proton pump inhibitors and risk of ischemic events in the general population.

A potential increased risk of cardiovascular events has been suggested for proton pump inhibitors (PPIs), the most commonly prescribed drugs for the management of upper gastrointestinal disorders. We ...

Medical and Biotech [MESH] Definitions

Integral membrane proteins that transport protons across a membrane. This transport can be linked to the hydrolysis of ADENOSINE TRIPHOSPHATE. What is referred to as proton pump inhibitors frequently is about POTASSIUM HYDROGEN ATPASE.

Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX.

A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS.

Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens.

The practice of prescribing medications in a manner that poses more risk than benefit, particularly where safer alternatives exist.

More From BioPortfolio on "Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial